


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) An activated A compound having a formula:




where

R^1 is selected from the group consisting of alkyl, $-\text{CH}_2(\text{OC}_2\text{H}_4)\text{OCH}_3$, and $-(\text{OC}_2\text{H}_4)\text{OCH}_3$;


n is 0-4;

Olig is an oligomer having a formula:



where:

L is a optional linker moiety selected from the group consisting of $-\text{CH}_2\text{O}-$, $-\text{CH}_2\text{OX}-$, $-\text{OX}-$, $-\text{C}(\text{O})-$, $-\text{C}(\text{O})\text{X}$, $-\text{NH}-$, $-\text{NHC}(\text{O})-$, $-\text{XNHC}(\text{O})-$, $-\text{NHC}(\text{O})\text{X}$, $-\text{C}(\text{O})\text{NH}-$, $-\text{C}(\text{O})\text{NHX}-$, and



where:

X is alkyl₁₋₆ or is not present,

Y is N or O or is not present, and

R^3 is alkyl₁₋₆;

PAG is a linear or branched polyalkylene glycol moiety;


R^2 is an alkyl₁₋₂₂ capping moiety if X is present or alkyl₂₋₂₂ if X is not present; and

q is a number from 1 to the maximum number of branches on PAG; and

m is 1-5; and wherein the activated compound comprises an activating moiety selected from the group consisting of chloroformate, NHS carbonate, DSC para-nitrochloroformate, p-nitrochloroformate, phosgene and paranitrophenyl carbonate.

2. (Original) The compound of claim 1 comprising an Olig coupled to carbon 4 of the phenol moiety.
3. (Original) The compound of claim 1 comprising an Olig coupled to carbon 3 of the phenol moiety, and/or an Olig coupled to carbon 5 of the phenol moiety.
4. (Original) The compound of claim 1 wherein m is 1 and the Olig is coupled to carbon 4 of the phenol moiety.
5. (Original) The compound of claim 1 wherein m is 1 and the Olig is coupled to carbon 3 or carbon 5 of the phenol moiety.
6. (Original) The compound of claim 1 wherein:
 - (a) m is 2, and
 - (b) a first Olig is coupled to carbon 3 of the phenol moiety, and
 - (c) a second Olig is coupled to carbon 5 of the phenol moiety.
7. (Original) The compound of claim 1 wherein L is present and X is not present.
8. (Original) The compound of claim 1 wherein L and X are both present.
9. (Original) The compound of claim 1 wherein PAG is a linear polyalkylene glycol moiety.
10. (Original) The compound of claim 1 wherein PAG is a linear polyethylene glycol moiety.
11. (Original) The compound of claim 1 wherein PAG is a branched polyalkylene glycol moiety.
12. (Original) The compound of claim 1 wherein PAG is a branched polyethylene glycol moiety.

13. (Original) The compound of claim 1 wherein q is 1 to 5.
14. (Original) The compound of claim 1 wherein q is 2.
15. (Original) The compound of claim 1 wherein R² is alkyl₅₋₁₂.
16. (Original) The compound of claim 1 wherein R² is alkyl₁₋₄.
17. (Original) The compound of claim 1 wherein X is present and R² is methyl.
18. (Original) The compound of claim 1 wherein R¹ is alkyl₁₋₂₂.
19. (Original) The compound of claim 1 wherein R¹ is alkyl₁₋₁₂.
20. (Original) The compound of claim 1 wherein R¹ is alkyl₁₋₆.
21. (Original) The compound of claim 1 wherein R¹ is methyl and L is not amide or O.
22. (Original) The compound of claim 1 wherein R¹ is methyl.
23. (Cancelled)
24. (Cancelled)
25. (Currently amended) A biologically active agent comprising a compound of claim 1 covalently coupled thereto by a carbamate bond to form a prodrug which does or does not retain the biological activity of the biologically active agent, wherein the biologically active agent is a drug moiety or a protein drug moiety.
26. (Currently amended) A ~~peptide or protein~~ drug moiety covalently coupled to one or more of the compound of claim 1.
27. (Withdrawn and amended) The compound of claim 1 having a formula:



wherein

X is an alkyl or is not present;

PEG is linear or branched PEG₂₋₅₀;


L is not included;

R is H or alkyl; and

n is a number from 1 to the maximum number of PEG branches.

28. (Cancelled)

29. (withdrawn) The compound of claim 1 having a formula:



wherein

X is an alkyl or is not present;


PEG is linear or branched PEG₂₋₅₀;

R is H or alkyl;

R' is alkyl; and

n is a number from 1 to the maximum number of PEG branches.

30. (Withdrawn and amended) The compound of claim 1 having a formula:



(Formula 5),

wherein

X ~~is an alkyl~~ or is not present;


PEG is linear or branched PEG₂₋₅₀;

L is not included;

R is H or alkyl; and

n is a number from 1 to the maximum number of PEG branches.

31. (Withdrawn and amended) The compound of claim 1 having a formula:



(Formula 6)

wherein

X ~~is an alkyl~~ or is not present;

PEG is linear or branched PEG₂₋₅₀;


L is not included;

m is 2;

R is H or alkyl; and

n is a number from 1 to the maximum number of PEG branches.

32. (Withdrawn and amended) The compound of claim 1 having a formula:



wherein


X is ~~an alkyl~~ or is not present;

PEG is linear or branched PEG₂₋₅₀;

R is H or alkyl; and

n is a number from 1 to the maximum number of PEG branches.

33. (Withdrawn and amended) The compound of claim 1 having a formula:



wherein

X is ~~an alkyl~~ or is not present;


n is 1-22;

PEG is linear or branched PEG₂₋₅₀;

R is H or alkyl; and

m is a number from 1 to the maximum number of PEG branches.

34. (Withdrawn) The compound of claim 1 having a formula:



wherein

PEG is linear or branched PEG₂₋₅₀;


R is H or alkyl;

n is 1 or 2; and

m is a number from 1 to the maximum number of PEG branches.


35. (Withdrawn) The compound of claim 34 wherein:

n is 2; and



is bound to the phenol moiety at positions 3 and 4.

36. (Currently amended) ~~The compound of claim 1~~ The compound of claim 1 having a formula:



wherein


X is an alkyl or is not present;

PEG is linear or branched PEG₂₋₅₀;


R is H or alkyl;

n is from 1 to the maximum number of PEG branches; and
R¹ is alkyl.


37. (withdrawn) The compound of claim 1 having a formula:




38. (Withdrawn and amended) The compound of claim 1 having a formula:




39. (withdrawn) The compound of claim 1 having a formula:




40. (withdrawn) The compound of claim 1 having a formula:




41. (withdrawn) The compound of claim 1 having a formula:



42. (withdrawn) The compound of claim 1 having a formula:




43. (Currently amended) A ~~The compound of claim 1~~ having a formula:



(Compound 7).

44. (Original) The compound of claim 1, wherein the compound is a pure prodrug or partial prodrug.
45. (Original) A pharmaceutical composition comprising the compound of claim 1 in a pharmaceutically acceptable carrier.
46. (Currently amended) A method of synthesizing the compound of claim 1, the method comprising: contacting a compound having a formula:




(Formula 1)

where

R^1 is selected from the group consisting of alkyl, $-\text{CH}_2(\text{OC}_2\text{H}_4)\text{OCH}_3$, and $-(\text{OC}_2\text{H}_4)\text{OCH}_3$;


n is 0-4;

Olig is an oligomer having a formula:



where:

L is a optional linker moiety selected from the group consisting of $-\text{CH}_2\text{O}-$, $-\text{CH}_2\text{OX}-$, $-\text{OX}-$, $-\text{C}(\text{O})-$, $-\text{C}(\text{O})\text{X}$, $-\text{NH}-$, $-\text{NHC}(\text{O})-$, $-\text{XNHC}(\text{O})-$, $-\text{NHC}(\text{O})\text{X}$, $-\text{C}(\text{O})\text{NH}-$, $-\text{C}(\text{O})\text{NHX}-$, and



where:

X is alkyl₁₋₆ or is not present,

Y is N or O or is not present, and

R³ is alkyl₁₋₆;

PAG is a linear or branched polyalkylene glycol moiety;

R² is an alkyl₁₋₂₂ capping moiety if X is present or alkyl₂₋₂₂ if X is not present; and

q is a number from 1 to the maximum number of branches on PAG; and

m is 1-5 with an activating moiety selected from the group consisting of chloroformate, NHS carbonate, DSC para-nitrochloroformate, p-nitrochloroformate, phosgene and paranitrophenyl carbonate in a solvent for a sufficient time to react the phenol group of (Formula 1) with the activating moiety.

47. (Currently amended) A method of treating a subject in need of treatment for diabetes comprising
~~that is comprising~~ administering an effective amount of the compound of claim 1 ~~to the subject~~
that is conjugated to insulin to the subject.